The evaluation on the left is that this would simply depress economic activity and tax revenues further, and would do nothing to slow down the escalation of the UK's national debt, except in the very short term.
Because vandetanib affects the electrical activity of the heart, potentially lethally, it is being sold under a Risk Evaluation and Mitigation Strategy (REMS).